StreetAccount Summary - Trading higher/lower: EU mid-morning
PureTech Presents New Data from Phase 2B Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF (125.0000p, 0)
Healthcare, financials, autos/parts and basic resources best performers; tech, retail and industrials lag:
Tang Capital Management LLC announces 3.07% stake in PureTech Health PLC - filing (pre-open) (110.2000p, +3.8)
StreetAccount Summary - European unusual volume traders
PureTech Health's Seaport Therapeutics advances second therapeutic candidate into clinical development with dosing of first participant in phase 1 study of GlyphAgo (115.2000p, -0.2)
StreetAccount Summary - US Pre-market trading update
Powered by FactSet Research Systems Inc.